4.7 Review

STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer

Journal

BIOMOLECULES
Volume 12, Issue 10, Pages -

Publisher

MDPI
DOI: 10.3390/biom12101450

Keywords

STAT3; pancreatic cancer; drug therapy; molecular targeted therapy

Funding

  1. National Natural Science Foundation of China [82260555]
  2. Gansu Traditional Chinese Medicine Research Project [GZKP-2020-28]
  3. Natural Science Foundation of Gansu Province [2020-0405-JCC-1871]
  4. Lanzhou City Chengguan District Science and Technology Plan Project [2020-2-11-4]

Ask authors/readers for more resources

This review discusses the relationship between STAT3 and pancreatic cancer, as well as the latest research on the use of STAT3 inhibitors in pancreatic cancer, aiming to provide insights and ideas for a new generation of chemotherapeutic modalities for pancreatic cancer.
The signal transducer and activator of transcription (STAT) is a family of intracellular cytoplasmic transcription factors involved in many biological functions in mammalian signal transduction. Among them, STAT3 is involved in cell proliferation, differentiation, apoptosis, and inflammatory responses. Despite the advances in the treatment of pancreatic cancer in the past decade, the prognosis for patients with pancreatic cancer remains poor. STAT3 has been shown to play a pro-cancer role in a variety of cancers, and inhibitors of STAT3 are used in pre-clinical and clinical studies. We reviewed the relationship between STAT3 and pancreatic cancer and the latest results on the use of STAT3 inhibitors in pancreatic cancer, with the aim of providing insights and ideas around STAT3 inhibitors for a new generation of chemotherapeutic modalities for pancreatic cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available